105 related articles for article (PubMed ID: 1567484)
1. In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.
Mullin RJ; Keith BR; Bigham EC; Duch DS; Ferone R; Heath LS; Singer S; Waters KA; Wilson HR
Biochem Pharmacol; 1992 Apr; 43(7):1627-34. PubMed ID: 1567484
[TBL] [Abstract][Full Text] [Related]
2. Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression.
Jansen M; Dykstra M; Lee JI; Stables J; Topley P; Knick VC; Mullin RJ; Duch DS; Smith GK
Biochem Pharmacol; 1994 Mar; 47(6):1067-78. PubMed ID: 8147906
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase.
Smith GK; Duch DS; Dev IK; Kaufmann SH
Cancer Res; 1992 Sep; 52(18):4895-903. PubMed ID: 1516046
[TBL] [Abstract][Full Text] [Related]
4. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
5. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.
Itoh F; Russello O; Akimoto H; Beardsley GP
Cancer Chemother Pharmacol; 1994; 34(4):273-9. PubMed ID: 8033293
[TBL] [Abstract][Full Text] [Related]
6. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
7. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
8. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
Kelley JL; McLean EW; Cohn NK; Edelstein MP; Duch DS; Smith GK; Hanlon MH; Ferone R
J Med Chem; 1990 Feb; 33(2):561-7. PubMed ID: 2299624
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
Pizzorno G; Davis SJ; Hartigan DJ; Russello O
Biochem Pharmacol; 1994 Jun; 47(11):1981-8. PubMed ID: 7516657
[TBL] [Abstract][Full Text] [Related]
11. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.
Hanlon MH; Ferone R; Mullin RJ; Keith BR
Cancer Res; 1990 Jun; 50(11):3207-11. PubMed ID: 2334916
[TBL] [Abstract][Full Text] [Related]
14. Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites.
Tse A; Moran RG
J Biol Chem; 1998 Oct; 273(40):25944-52. PubMed ID: 9748271
[TBL] [Abstract][Full Text] [Related]
15. Side chain modified 5-deazafolate and 5-deazatetrahydrofolate analogues as mammalian folylpolyglutamate synthetase and glycinamide ribonucleotide formyltransferase inhibitors: synthesis and in vitro biological evaluation.
Rosowsky A; Forsch RA; Reich VE; Freisheim JH; Moran RG
J Med Chem; 1992 May; 35(9):1578-88. PubMed ID: 1578484
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
[TBL] [Abstract][Full Text] [Related]
17. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
18. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
19. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
20. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
